Difference between revisions of "Category:Anti-SLAMF7 antibodies"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "Category:Antibody medications" to "Category:Antineoplastic monoclonal antibodies") |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
| − | Drugs that have some demonstrated degree of efficacy through the inhibition of Signaling Lymphocytic Activation Molecule Family member 7 (SLAMF7). Elotuzumab is the first FDA-approved medication in this category. | + | Drugs that have some demonstrated degree of efficacy through the inhibition of Signaling Lymphocytic Activation Molecule Family member 7 (SLAMF7), also commonly called CS1. [[Elotuzumab (Empliciti)|Elotuzumab]] is the first FDA-approved medication in this category. |
| − | [[Category: | + | [[Category:Antineoplastic monoclonal antibodies]] |
Latest revision as of 20:01, 27 February 2020
Drugs that have some demonstrated degree of efficacy through the inhibition of Signaling Lymphocytic Activation Molecule Family member 7 (SLAMF7), also commonly called CS1. Elotuzumab is the first FDA-approved medication in this category.
Pages in category "Anti-SLAMF7 antibodies"
This category contains only the following page.